Strengths
- 2021 unicorn valuation supported by CB Insights/financing evidence.
- Vertex, Bayer and Regeneron partnerships are publicly evidenced.
- Founder list including Jennifer Doudna is public.
Diligence report
Mammoth Biosciences
Mammoth Biosciences Public-Source Standard Diligence Report
Proceed only with confirmatory data-room, technical, IP, regulatory and contract diligence. Upside depends on compact in vivo CRISPR systems translating into clinical assets and partner milestones; downside is financial opacity, preclinical risk and milestone dependency.
Company profile
Mammoth Biosciences Public-Source Standard Diligence Report
Mammoth Biosciences has strong public signals: credible CRISPR founder/science pedigree, 2021 unicorn financing, and major pharma collaborations. Public diligence remains insufficient on financial quality, clinical readiness, IP/FTO, customer economics, suppliers and legal/regulatory clearance.
- Website
- mammoth.bio
- Sector
- Healthcare & Life Sciences / Biotechnology / CRISPR gene editing and diagnostics
- Geography
- United States; Brisbane, California
- Stage
- Private unicorn / venture-backed biotechnology platform
- Known aliases
- Mammoth Biosciences, Inc., Mammoth Bio
- Report version
- 1.0
- Timezone
- America/Los_Angeles
Executive summary
Risks
- Financial quality not publicly verifiable.
- Preclinical translation and delivery risk.
- Partner and milestone dependency.
Gaps
- Financial statements, revenue, cash runway and cap table.
- Executed partner agreements and milestone status.
- Preclinical/CMC/IND/clinical status and patent/FTO opinions.
- HR, supplier, EHS, litigation, insurance and material contract files.
Risk register
R-001: Financial quality not publicly verifiable
No public audited financials, revenue, burn, runway, cap table, or unit economics.
Diligence request: Request full financial/cap-table data room.
R-002: Preclinical translation and delivery risk
Value depends on compact in vivo editing, delivery, specificity, safety, CMC, IND and clinical proof.
Diligence request: Run technical, CMC and clinical diligence.
R-003: Partner and milestone dependency
Public validation is dominated by contingent partner milestones rather than recurring revenue.
Diligence request: Review contracts, milestones, revenue recognition and termination rights.
R-004: IP/FTO uncertainty
CRISPR IP landscape is complex; public indexes do not prove ownership, claims or freedom-to-operate.
Diligence request: Obtain patent counsel opinion and assignment/license records.
R-005: Clinical and regulatory path uncertainty
Therapeutic clinical status was inconclusive and diagnostics EUA history requires official verification.
Diligence request: Regulatory counsel to verify FDA/EUA/IND/ClinicalTrials.
R-008: Intense gene-editing competition
CRISPR/gene-editing competitors have approved products, clinical data, capital and partnerships.
Diligence request: Build indication-by-indication competitor map.
R-010: Supplier/lab/CMC dependencies undisclosed
Delivery, CDMO, reagent, lab quality and data-system dependencies are not publicly mapped.
Diligence request: Request supplier list, CDMO contracts, quality audits and lab audit.
R-006: Team scale and retention unverified
Public headcount/org data are directional; compensation, equity and turnover are private.
Diligence request: Request HRIS, payroll, org chart and equity/comp materials.
01Financial Information
Financing and unicorn valuation are public; financial statements, projections, cap table and tax/accounting details are private.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: high
No audited/management financials, revenue, backlog or AR aging were public.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide audited financials, monthly accounts, revenue, deferred revenue, backlog and AR aging.
| metric | public signal | status | request |
|---|---|---|---|
| Revenue/ARR | Not disclosed | not_publicly_verifiable | Audited revenue, ARR, deferred revenue |
| Margins/COGS | Not disclosed numerically | not_publicly_verifiable | COGS and margin by product |
| Runway/burn/backlog/AR | Not disclosed | not_publicly_verifiable | Cash, burn, backlog, AR aging |
I.B Financial Projections
not publicly verifiable confidence: high
Public upside is partner/pipeline driven, but forecasts and assumptions are private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide board plan, forecast model, cash runway and milestone probability schedule.
I.C Capital Structure
partially verified confidence: medium
Investor names are public; ownership, securities, debt and off-balance-sheet liabilities are private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide cap table, option ledger, SAFEs/notes, debt and investor rights.
| stakeholder | public position | diligence caveat | status |
|---|---|---|---|
| Mayfield, NFX, Plum Alley | Listed investors | Percent ownership/rights not public | verified |
| Other investors | Redmile, Foresite, Sixth Street, Decheng, Verily and others public | Share class, liquidation preference, board/control rights private | partially_verified |
| Options/warrants/notes/debt | Not disclosed | Request ledger and debt instruments | not_publicly_verifiable |
I.D Other financial information
partially verified confidence: high
Financing history is the strongest public financial evidence; tax and accounting policies are not public.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide tax/NOL schedules, revenue recognition policies and complete financing history.
| date | round | amount | participants | valuation signal | status |
|---|---|---|---|---|---|
| 2020 | Series C | $45M | Redmile, Foresite, Amazon/existing investors | Not public | partially_verified |
| 2021-09-09 | Series D / financing package | $195M disclosed; $150M Series D context | Redmile, Foresite, Sixth Street, Mayfield, Decheng, NFX, Plum Alley, others | >$1B / CB Insights $1.00B | verified |
02Products
Public products are in vivo CRISPR therapeutics, protein discovery, and DETECTR diagnostics; pricing, margin and commercial traction are not public.
II.A Description of each product
partially verified confidence: medium
Mammoth discloses compact CRISPR therapeutic and DETECTR diagnostic platforms; growth, share, cost and profitability require private evidence.
Evidence gaps
- Pricing, margins, market share, customers, clinical proof and product P&Ls are not public.
Follow-up questions
- Provide product roadmap, pricing, COGS, margins, adoption, preclinical/clinical data.
| product | audience | features | status |
|---|---|---|---|
| In vivo CRISPR therapeutics | Patients/partners | Ultracompact systems; LNP/AAV; modalities beyond DSB | partially_verified |
| Protein discovery | Internal/partners | Metagenomic data, AI, wet-lab screening | partially_verified |
| DETECTR diagnostics | Providers/partners | CRISPR nucleic-acid detection | verified |
| offering | public pricing | benchmark | status | request |
|---|---|---|---|---|
| Therapeutics | Not public | Approved gene therapies show path but not Mammoth economics | not_publicly_verifiable | Pricing/reimbursement and CMC cost model |
| DETECTR | Not public | COVID EUA-era diagnostics | not_publicly_verifiable | Current test menu, price, COGS, customers |
| Platform deals | Upfronts/milestones public | Milestone-heavy biotech collaborations | partially_verified | Revenue recognition and contracts |
03Customer Information
Public customer evidence is partner-led; top customers, revenue by customer, severed relationships and suppliers are private.
III.A Top customers by application
partially verified confidence: medium
No top-15 customer list was public; partners are the public customer substitutes.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide top customers/partners by revenue/application and purchase timing.
| counterparty | use case | public economics | status |
|---|---|---|---|
| Vertex | Two in vivo gene-editing programs | $41M upfront; up to $650M potential | verified |
| Bayer | Five in vivo indications; liver first | $40M upfront; potential >$1B | verified |
| Regeneron | Multiple tissues/cell types | $100M upfront/equity; up to $370M/target | verified |
| End customers | Diagnostics/therapeutics | Not public | not_publicly_verifiable |
III.B Strategic relationships
verified confidence: high
Vertex, Bayer and Regeneron relationships are publicly evidenced with upfront and milestone economics.
Evidence gaps
- Underlying contracts and current status are private.
Follow-up questions
- Provide executed agreements, amendments, milestones, terminations and governance minutes.
| partner | date | scope | economics | gap |
|---|---|---|---|---|
| Vertex | 2021-10-26 | Two genetic diseases | $41M upfront; up to $650M | Current status/termination/exclusivity |
| Bayer | 2022-01-10 | Five in vivo indications | $40M upfront; >$1B potential | Option exercise/milestones |
| Regeneron | 2024-04-25 | Multiple tissues/cell types | $100M upfront/equity; $370M/target potential | Target count/profit-share/current workplan |
Headline deal value is contingent.
III.C Revenue by customer
not publicly verifiable confidence: high
Revenue by customer is not public; announced milestones should not be treated as recurring revenue.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide revenue by customer, deferred revenue and concentration schedule.
III.D Significant relationships severed within the last two years
not publicly verifiable confidence: low
No severed relationships were verified publicly; company confirmation is required.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide terminated, expired, paused or disputed relationships since 2024.
III.E Top suppliers
not publicly verifiable confidence: medium
Top suppliers are not public; delivery/lab/CMC dependencies are material.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide supplier spend, CDMO contracts, quality audits and business-continuity plans.
| category | role | public evidence | risk | status |
|---|---|---|---|---|
| LNP/AAV/novel delivery | In vivo delivery | Therapeutics page references LNP/AAV/etc. | Single-source or immature delivery dependencies | not_publicly_verifiable |
| Reagents/synthesis/screening | Discovery and wet-lab work | Protein discovery page | Reagent/data-system dependency unknown | not_publicly_verifiable |
| CDMO/quality/manufacturing | Clinical/diagnostic supply | Not public | CMC bottleneck | not_publicly_verifiable |
04Competition
Mammoth competes in a crowded CRISPR/gene-editing field where delivery, IP, modality, clinical data, capital and partners matter.
IV.A Competitive landscape by market segment
partially verified confidence: medium
FDA approval of gene therapies and public CRISPR peers validate the field but raise competitive bar.
Evidence gaps
- No paid market study, customer perception study or competitor interviews reviewed.
Follow-up questions
- Benchmark competitors by indication, modality, delivery, IP, clinical stage and capital.
| competitor | segment | overlap | stage signal | risk |
|---|---|---|---|---|
| CRISPR Therapeutics/Vertex | CRISPR gene therapy | Gene editing | Casgevy approval context | Commercially ahead |
| Intellia | In vivo CRISPR | In vivo delivery/editing | SEC public peer | Clinical/capital lead |
| Editas/Beam/Prime/Scribe/Arbor/Caribou | Editing platforms | Cas/base/prime/delivery/IP | Public filings/search landscape | Crowded IP and partner market |
| axis | mammoth position | competitor pressure | status |
|---|---|---|---|
| Cargo size/delivery | Ultracompact CRISPR claim | High | partially_verified |
| Clinical maturity | Public pipeline; clinical status inconclusive | High | partially_verified |
| Partner validation | Vertex/Bayer/Regeneron | Medium-high | verified |
| anchor | relevance | mammoth implication | source |
|---|---|---|---|
| Casgevy/Lyfgenia FDA approval | Regulatory path exists | Competitor bar rises | FDA |
| Public CRISPR SEC peers | Benchmarks risk and spend | Compare pipeline/capital | SEC |
| Mammoth partner deals | Pharma platform validation | Milestone dependency | Partner releases |
05Marketing, Sales, and Distribution
GTM appears partner/science/PR-led; sales productivity and budgets are private.
V.A Strategy and implementation
partially verified confidence: medium
Public strategy emphasizes partnerships, platform science and internal pipeline.
Evidence gaps
- Marketing budget, channel contracts and ROI not public.
Follow-up questions
- Provide marketing plan, BD pipeline and channel contracts.
| channel | region | evidence | gap | status |
|---|---|---|---|---|
| Pharma/biotech collaborations | Global partners | Vertex/Bayer/Regeneron | Pipeline/conversion/exclusivity | verified |
| Internal therapeutic development | U.S./future regulated markets | MB-111 public pipeline | Clinical/commercial plan | partially_verified |
| Diagnostics partner integration | Not disclosed | DETECTR integration by Mammoth or partners | Current customers/pricing/status | partially_verified |
| signal | example | interpretation | sources |
|---|---|---|---|
| Scientific credibility | DETECTR, Cas14, CasPhi papers | Technical thought leadership | SRC-015/016/017 |
| Financing PR | $195M/unicorn announcement | Investor validation | SRC-007/008 |
| Partner PR | Vertex/Bayer/Regeneron | BD-led GTM validation | SRC-009/010/011 |
V.B Major Customers
not publicly verifiable confidence: medium
Major-customer status and trends are private beyond public collaborations.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide account plans, QBRs, pipeline by partner and milestone status.
V.C Principal avenues for generating new business
partially verified confidence: medium
Principal public avenues are pharma/biotech partnerships, pipeline advancement and diagnostics integration.
Evidence gaps
- Lead sources and conversion rates not public.
Follow-up questions
- Provide BD funnel, win/loss, term-sheet and partner target list.
V.D Sales force productivity model
not publicly verifiable confidence: high
No quota, compensation, sales cycle or new-hire model was public.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide sales/BD comp, CRM exports, quotas, cycle data and hiring plan.
| metric | public status | why it matters | request |
|---|---|---|---|
| BD funnel | Not public | Repeatability | CRM export |
| Quota/comp/sales cycle | Not public | Efficiency | Comp plans and cycle data |
| Marketing/BD budget | Not public | Runway/capacity | Budget-to-actuals and headcount plan |
V.E Ability to implement marketing plan with current and projected budgets
not publicly verifiable confidence: high
Budget capacity cannot be assessed without runway and operating plan.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide budget-to-actuals, board plan, runway and staffing plan.
06Research and Development
R&D is the core asset: compact systems, discovery engine, publications and MB-111; reproducibility, readiness and costs are private.
VI.A Description of R&D organization
partially verified confidence: medium
Company sources describe metagenomic/AI discovery, wet-lab screening and engineering; publications support technical roots.
Evidence gaps
- R&D budget, lab notebooks, data rights, assay validation and personnel allocation are private.
Follow-up questions
- Provide R&D org chart, budgets, study reports, assay validation, lab notebooks and IP assignments.
| person or role | public signal | relevance | status |
|---|---|---|---|
| Jennifer Doudna | Co-founder/Nobel laureate | Scientific credibility | verified |
| Janice Chen / Lucas Harrington | Co-founders | Science/product/IP assignment | verified |
| R&D organization | Discovery/wet-lab workflow | Pipeline execution | partially_verified |
| year | publication | relevance | status |
|---|---|---|---|
| 2018 | Cas14 Science paper | Miniature CRISPR systems | verified |
| 2020 | DETECTR Nature Biotechnology paper | Diagnostics platform | verified |
| 2020 | CasPhi Science paper | Hypercompact genome editor | verified |
VI.B New Product Pipeline
partially verified confidence: medium
MB-111 and partnered programs are public at a high level; cost, timing, IND and clinical status are not fully public.
Evidence gaps
- Development cost, IND-enabling package, toxicology, CMC and clinical timing are not public.
Follow-up questions
- Provide pipeline stage gates, IND plan, toxicology/CMC status and regulatory correspondence.
| project | status public | scope | partner | gap |
|---|---|---|---|---|
| MB-111 | Public pipeline row | FCS + SHTG; liver; ultracompact nuclease knockout; LNP | Internal | IND/CMC/toxicology/trial status |
| Vertex programs | Collaboration announced | Two genetic diseases | Vertex | Current program/milestones |
| Bayer/Regeneron programs | Collaborations announced | Liver/multiple tissues/cell types | Bayer/Regeneron | Targets/status/milestones |
07Management and Personnel
Founder pedigree and directional headcount are public; org chart, compensation, equity, relations and turnover are private.
VII.A Organization Chart
partially verified confidence: medium
No formal company org chart was public; external org source is directional.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide current org chart, reporting lines, vacancies and succession plan.
Reporting lines schematic; verify with company org chart.
VII.B Historical and projected headcount by function and location
partially verified confidence: medium
LinkedIn range and HQ address are directional; historical/projected headcount by function/location is private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide HRIS, payroll, function/location breakdown, contractors and hiring plan.
| signal | public value | source | caveat |
|---|---|---|---|
| Headcount range | 201-500 employees (reported) | Self-reported/directional | |
| HQ | 1000 Marina Blvd., Brisbane, CA | Company page | Other sites not verified |
| Hiring | Careers/we are hiring signal | Company homepage | Open roles/hiring plan not fully reviewed |
VII.C Senior management biographies
partially verified confidence: medium
Founder list is public; current bios and responsibilities need confirmation.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide management bios, resumes, references, employment terms and outside obligations.
| name | public role | relevance | status |
|---|---|---|---|
| Trevor Martin | Co-founder/executive signal | Leadership verification | partially_verified |
| Jennifer Doudna | Co-founder/scientific founder | Scientific credibility | verified |
| Janice Chen / Lucas Harrington | Co-founders | R&D/IP diligence | verified |
| Elaine Sun | External org-chart executive signal | Role verification | partially_verified |
VII.D Compensation arrangements
not publicly verifiable confidence: high
Compensation, benefits and severance are private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide compensation census, benefits, employment and severance agreements.
| topic | public status | priority | request |
|---|---|---|---|
| Compensation/employment agreements | Not public | high | Executive agreements and comp census |
| Stock plans/options | Not public | high | Stock plan, option ledger, 409A |
| Employee relations/turnover | Not public | medium | Attrition, complaints, investigations |
VII.E Incentive stock plans
not publicly verifiable confidence: high
Stock plans, grants, exercise prices and vesting are private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide stock plans, option ledger, grant notices and 409A valuations.
VII.F Significant employee relations problems, past or present
not publicly verifiable confidence: low
No public employee-relations matters were verified, but absence cannot be confirmed publicly.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide HR/legal matter log, complaints, investigations and settlements.
VII.G Personnel Turnover
not publicly verifiable confidence: high
Turnover and retention data are private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide attrition by function/location and retention/benefit plans.
08Legal and Related Matters
IP/trademark and diagnostics regulatory signals are public; litigation, contracts, insurance, EHS, regulatory status and legal opinions require counsel/private files.
VIII.A Pending lawsuits against the Company
inconclusive confidence: low
No confirmed pending lawsuits were extracted publicly; counsel review not performed.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Have counsel perform PACER/state/arbitration/PTAB/ITC/demand-letter searches.
| source | status | caveat | request |
|---|---|---|---|
| CourtListener | No confirmed material case extracted | Search URL only | Counsel docket sweep |
| Law360 | Paywalled company page identified | Articles not reviewed | Legal-news/docket review |
| State/arbitration/demand letters | Not public | Cannot clear publicly | Company legal schedule |
VIII.B Pending lawsuits initiated by Company
inconclusive confidence: low
No confirmed Mammoth-initiated lawsuits were extracted publicly.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide litigation schedule, IP enforcement and dispute records.
| matter | public status | status | request |
|---|---|---|---|
| Mammoth-initiated court actions | Not confirmed | inconclusive | Counsel docket search |
| IP enforcement/PTAB/ITC | Not reviewed | not_publicly_verifiable | Patent counsel search |
| Contract/arbitration disputes | Not public | not_publicly_verifiable | Dispute/notice schedule |
VIII.C Environmental and employee safety issues and liabilities
not publicly verifiable confidence: low
Lab/EHS/OSHA/environmental records are not public.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide EHS policies, permits, OSHA logs, incident reports and lab audits.
| area | public evidence | status | request |
|---|---|---|---|
| Diagnostics EUA | FDA EUA framework; DETECTR IFU/revocation sources access-limited | partially_verified | Retrieve official letters/revocations |
| Therapeutic regulatory status | Pipeline public; ClinicalTrials access inconclusive | inconclusive | IND/FDA/ClinicalTrials verification |
| Insurance/contracts/EHS | Not public beyond partnership headlines | not_publicly_verifiable | Policies, contracts, EHS, lab audits |
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
Patent/trademark indexes support IP assets but not legal conclusions.
Evidence gaps
- Assignments, licenses, FTO and encumbrances require counsel.
Follow-up questions
- Provide patent-family chart, official assignments, licenses and FTO opinion.
| asset | source | public status | diligence need |
|---|---|---|---|
| CRISPR/Cas patent publications | Google Patents | Mammoth assignee search signal | Official assignments, family chart, FTO |
| DETECTR trademark | USPTO.report | Application #88853203 filed 2020-03-30 | Official TSDR status |
| Cas14/CasPhi rights | Science and patent indexes | Public science; rights chain not reviewed | University/company licenses, government rights |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: high
Insurance coverage and claims history are private.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide policies, broker summary, claims, exclusions and coverage limits.
VIII.F Material contracts
not publicly verifiable confidence: high
Executed material contracts are not public beyond headline announcements.
Evidence gaps
- Private company records required; not publicly verifiable from reviewed sources.
Follow-up questions
- Provide material contract list, executed agreements, amendments, termination notices and leases.
VIII.G Regulatory agency problems
partially verified confidence: medium
Diagnostics EUA history and therapeutic regulatory status require official retrieval/counsel confirmation.
Evidence gaps
- FDA correspondence, INDs, inspections and ClinicalTrials status not fully public.
Follow-up questions
- Regulatory counsel should retrieve EUA letters/revocations, IND/FDA correspondence and registry status.
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights/user row lists Mammoth Biosciences as a Brisbane, U.S. Healthcare & Life Sciences unicorn with $1.00B valuation, joined 2021-09-09, selected investors NFX, Plum Alley, Mayfield. | verified high | SRC-001 |
| EC-002 | Mammoth says it is a biotechnology company using proprietary ultracompact CRISPR systems for potential long-term curative therapies; it lists founders Jennifer Doudna, Trevor Martin, Janice Chen, Lucas Harrington and Brisbane address. | verified medium | SRC-003 |
| EC-003 | Mammoth describes discovery via metagenomic databases, proprietary AI algorithms, wet-lab screening, and engineering. | partially verified medium | SRC-005 |
| EC-004 | Mammoth describes DETECTR as a CRISPR-based molecular diagnostics platform using CRISPR nucleases to find defined gene sequences and generate signal. | verified medium | SRC-006 |
| EC-005 | Business Wire says Mammoth secured $195M financing, comprising $150M Series D after $45M Series C, and joined unicorn ranks above $1B valuation. | verified high | SRC-007SRC-008 |
| EC-006 | Vertex collaboration announced $41M upfront and up to $650M potential future payments across two programs. | verified high | SRC-009 |
| EC-007 | Bayer collaboration announced $40M upfront and potential future payments above $1B across five preselected in vivo indications. | verified high | SRC-010 |
| EC-008 | Regeneron collaboration announced $100M upfront/equity and up to $370M per target in milestones. | verified high | SRC-011 |
| EC-009 | FDA EUA framework says EUA tests can continue only if available, not expired and not revoked; DETECTR IFU and revocation sources require counsel confirmation because direct access was restricted. | partially verified medium | SRC-012SRC-013SRC-014 |
| EC-010 | Peer-reviewed/publication sources support DETECTR, Cas14 and CasPhi technical foundations. | verified medium | SRC-015SRC-016SRC-017 |
| EC-011 | Public patent/trademark indexes show Mammoth-associated CRISPR/Cas patent publications and DETECTR trademark application #88853203, but official assignments/FTO were not reviewed. | partially verified medium | SRC-018SRC-019 |
| EC-012 | Mammoth public pipeline includes internal liver program MB-111 for FCS + SHTG using ultracompact nuclease knockout with LNP delivery; clinical-trial status was inconclusive due access limits. | partially verified medium | SRC-004SRC-020 |
| EC-013 | No public audited financial statements, revenue/ARR, margins, backlog, AR aging, cap table, debt, tax, or unit economics were found in reviewed public sources. | not publicly verifiable high | SRC-003SRC-007SRC-009SRC-010SRC-011 |
| EC-014 | Public customer evidence is concentrated in Vertex, Bayer and Regeneron partner announcements; revenue by customer, top customers, severed relationships and supplier concentration are not public. | partially verified high | SRC-009SRC-010SRC-011 |
| EC-015 | Gene-editing competition is intense; FDA approved Casgevy/Lyfgenia and public CRISPR peers file with SEC. | partially verified medium | SRC-023SRC-024SRC-025SRC-026 |
| EC-016 | Public GTM signals are partnership-led and science/PR-led; no salesforce productivity, funnel conversion, quota, or marketing budget data were public. | partially verified medium | SRC-003SRC-006SRC-009SRC-010SRC-011 |
| EC-017 | LinkedIn/external org sources provide directional headcount and executive signals, but HRIS, compensation, equity, turnover and employee-relations data are private. | partially verified medium | SRC-021SRC-022SRC-003 |
| EC-018 | Legal, contracts, insurance, EHS, suppliers, CDMOs, and material regulatory/legal matters could not be cleared from public sources; CourtListener/Law360 searches were not substitutes for counsel. | inconclusive low | SRC-027SRC-028SRC-003SRC-004 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.